Diaphorina citri psyllid: psy17080

Local Sequence Feature Prediction

Prediction and MethodResult
Residue Number Marker
Protein Sequence ?
Secondary Structure (Consensus) ?
Disordered Region (Consensus) ?
Transmembrane Helix (Consensus) ?
Signal Peptide (Consensus) ?
Coiled Coil (COILS) ?
 
--------10--------20--------30--------40--------50--------60--------70--------80--------90-------100-------110-------120-------130-------140-------150-------160-------170-------180-------190-------200-------210-------220-------230-------240-------250-------260-------270-------280-------290-------300-------310-------320-------330-------340-------350-------360-------370-------380-------390-------400-------410-------420-------430-------440-------450-------460-------470-------480-------490-------500-------510-------520-------530-------540-------550-------560-----
AASNNNTVGILNVAVSTQTDPYTPDVPEDVINSAIGDFGKWQFQLTLFLSLLNIPCTWHIFALTFQGASQDFWCTIPASLSTLTLDQWKNLSSISGVPYNPCNILDLDYSLPYSTLLNIRRDVTAVRPCLQWTYDSSSFGHTIISEWDLVCSNSSLESLAEMVFLLGVAFGGFFSGLVSDKFGRKKALMGSLVFQLVLGVLVAISPWFELYLVVRFFLGFFCVSIVFSGFVLCMELVGGKWLTIMGVMYLFPVPVGYIAISGIAYYSHNWRLLQWVITIPTIFFLTLWWIMPESPRWLVSMGRNKEAMKILGDAAKFNSRKLPLNLEKLLKESVLSTNQDVGKKVQVMDLWRTPLIRLISFVQYIIWFSVYLVYYGLVLNLSNIGGDVYLNTIISGIVEFPAIVISIFILLKMGRRRPLCLTTLGAGLACLMTLGFAPGSFITISLAMVGKFAISSSNVIIPIYTAELFPTKMRNLGVGASSVPAGVALILIPYLWHMQSINIHFPMGLLGVVGVLGGLSVLLLPDTTGLADNLHQLENDVPIQTPLVSTPIKRRKLNLWRKPYA
cccccccccccccccccccccccccccHHHHHHHccccccHHHHHHHHHHHHHHHHHHHHHHHcHHccccccccccccccccccHHHHHcccccccccccccccccccccccccccccccccccccccccccEEccccccccccccccEEcccccccHHHHHHHHHHHHHHHHHHcccHHHcccHHHHHHHHHHHHHHHHHHEEccHHHHHHHHHHHHHHHHHHHHHHHHHHHcccccccHHHHHHHHHHcHHHHHHHHHHHHHHHHcHHHHHHHHHHHHHHHHHHHHHcccccHHHHHHcccHHHHHHHHHHHHHHccccccHHHHHHHHHHHHHHcccccccccccccccccHHHHHHHHHHHHHHHHHHHEEEEEEccccccccHHHHHHHHHHHHHHHHHHHHHHHccccccHHHHHHHHHHHHHHHHHHHcccccHHHHHHHHHHHHHHHHHccHHHHHccccccHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHccHHHHHHHHHHHHHHHHHccccccccccHHHHHHccccccccccccHHHccccccccccc
***********************PDVPEDVINSAIGDFGKWQFQLTLFLSLLNIPCTWHIFALTFQGASQDFWCTIPASLSTLTLDQWKNLSSISGVPYNPCNILDLDYSLPYSTLLNIRRDVTAVRPCLQWTYDSSSFGHTIISEWDLVCSNSSLESLAEMVFLLGVAFGGFFSGLVSDKFGRKKALMGSLVFQLVLGVLVAISPWFELYLVVRFFLGFFCVSIVFSGFVLCMELVGGKWLTIMGVMYLFPVPVGYIAISGIAYYSHNWRLLQWVITIPTIFFLTLWWIMPESPRWLVSMGRNKEAMKILGDAAKFNSRKLPLNLEKLLKESVLSTNQDVGKKVQVMDLWRTPLIRLISFVQYIIWFSVYLVYYGLVLNLSNIGGDVYLNTIISGIVEFPAIVISIFILLKMGRRRPLCLTTLGAGLACLMTLGFAPGSFITISLAMVGKFAISSSNVIIPIYTAELFPTKMRNLGVGASSVPAGVALILIPYLWHMQSINIHFPMGLLGVVGVLGGLSVLLLPDTTGLADNLHQLEND*************************
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxHHHHHHHHHHHHHHHHHxxxxxxxxxHHHHHHHHHHHHHHHHHHHHHxxxxxxxHHHHHHHHHHHHHHHHHHHxxxxxxxxxxxHHHHHHHHHHHHHHHHHHHHHxxxxxHHHHHHHHHHHHHHHHHHHHxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxHHHHHHHHHHHHHHHHHHHHHHHxxxxxxxxxHHHHHHHHHHHHHHHHHHHHHHHxxxxxxHHHHHHHHHHHHHHHHHHHHxxxxHxxHHHHHHHHHHHHHHHHHHHHxxxxxxxxxxxHHHHHHHHHHHHHHHHHHHHHHxxxxxxHHHHHHHHHHHHHHHHHHHHHxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
AASNNNTVGILNVAVSTQTDPYTPDVPEDVINSAIGDFGKWQFQLTLFLSLLNIPCTWHIFALTFQGASQDFWCTIPASLSTLTLDQWKNLSSISGVPYNPCNILDLDYSLPYSTLLNIRRDVTAVRPCLQWTYDSSSFGHTIISEWDLVCSNSSLESLAEMVFLLGVAFGGFFSGLVSDKFGRKKALMGSLVFQLVLGVLVAISPWFELYLVVRFFLGFFCVSIVFSGFVLCMELVGGKWLTIMGVMYLFPVPVGYIAISGIAYYSHNWRLLQWVITIPTIFFLTLWWIMPESPRWLVSMGRNKEAMKILGDAAKFNSRKLPLNLEKLLKESVLSTNQDVGKKVQVMDLWRTPLIRLISFVQYIIWFSVYLVYYGLVLNLSNIGGDVYLNTIISGIVEFPAIVISIFILLKMGRRRPLCLTTLGAGLACLMTLGFAPGSFITISLAMVGKFAISSSNVIIPIYTAELFPTKMRNLGVGASSVPAGVALILIPYLWHMQSINIHFPMGLLGVVGVLGGLSVLLLPDTTGLADNLHQLENDVPIQTPLVSTPIKRRKLNLWRKPYA

Function Prediction

Annotation transfered from Closely Related SWISS-PROT Entries ?

Annotation ?Function Description ?Confidence Level ?Reference Protein ?
Solute carrier family 22 member 2 Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), 1-methyl-4-phenylpyridinium (MPP), cisplatin and oxaliplatin. Cisplatin may develop a nephrotoxic action. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX. This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity (By similarity). Mediates tubular uptake of tetraethylammonium (TEA) and cimetidine.confidentQ8MJI6
Solute carrier family 22 member 2 Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, serotonin, choline, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP and amiloride (By similarity). Mediates the influx of adrenaline, noradrenaline (norepinephrine), dopamine, cimetidine, famotidine, metformin, N-1-methylnicotinamide (NMN), 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), oxaliplatin and cisplatin. Cisplatin may develop a nephrotoxic action. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX. This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity.confidentQ9R0W2
Solute carrier family 22 member 2 Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, cisplatin and oxaliplatin. Cisplatin may develop a nephrotoxic action. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX. This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity.confidentQ5R5H7

Prediction of Gene Ontology Terms ?

GO Term ?Description ?Confidence Level ?Parent GO Terms ?
GO:0016323 [CC]basolateral plasma membraneprobableGO:0016020, GO:0044464, GO:0005623, GO:0005575, GO:0071944, GO:0005886, GO:0044425, GO:0044459
GO:0016324 [CC]apical plasma membraneprobableGO:0045177, GO:0016020, GO:0044464, GO:0005623, GO:0005575, GO:0071944, GO:0005886, GO:0044425, GO:0044459
GO:0005887 [CC]integral to plasma membraneprobableGO:0031226, GO:0016021, GO:0016020, GO:0044464, GO:0005623, GO:0005575, GO:0071944, GO:0005886, GO:0044425, GO:0044459, GO:0031224
GO:0015491 [MF]cation:cation antiporter activityprobableGO:0022891, GO:0015297, GO:0022892, GO:0015291, GO:0005215, GO:0008324, GO:0015298, GO:0015075, GO:0022857, GO:0003674, GO:0022804
GO:0006783 [BP]heme biosynthetic processprobableGO:0006778, GO:0006779, GO:0044249, GO:0034641, GO:0006807, GO:1901362, GO:1901360, GO:1901576, GO:0044710, GO:0051186, GO:0042440, GO:0051188, GO:0071704, GO:0033014, GO:0033013, GO:0018130, GO:0042168, GO:0009987, GO:0006725, GO:0009058, GO:0008150, GO:0008152, GO:1901564, GO:0046148, GO:0046483, GO:0044271, GO:1901566, GO:0044237, GO:0019438
GO:0040018 [BP]positive regulation of multicellular organism growthprobableGO:0040014, GO:0051240, GO:0050789, GO:0065007, GO:0051239, GO:0048518, GO:0008150, GO:0040008, GO:0045927
GO:0008513 [MF]secondary active organic cation transmembrane transporter activityprobableGO:0022891, GO:0022892, GO:0015291, GO:0005215, GO:0008324, GO:0015075, GO:0022857, GO:0015101, GO:0003674, GO:0022804
GO:0019534 [MF]toxin transporter activityprobableGO:0005215, GO:0003674
GO:0043234 [CC]protein complexprobableGO:0005575, GO:0032991
GO:0006915 [BP]apoptotic processprobableGO:0010259, GO:0009987, GO:0012501, GO:0044763, GO:0008150, GO:0007569, GO:0044699
GO:0009705 [CC]plant-type vacuole membraneprobableGO:0005737, GO:0005575, GO:0000325, GO:0031090, GO:0005773, GO:0016020, GO:0044464, GO:0043229, GO:0005623, GO:0005774, GO:0044446, GO:0044444, GO:0044437, GO:0044424, GO:0005622, GO:0043227, GO:0043226, GO:0044422, GO:0043231
GO:0005452 [MF]inorganic anion exchanger activityprobableGO:0022891, GO:0015297, GO:0022892, GO:0015291, GO:0015301, GO:0005215, GO:0008509, GO:0015075, GO:0022857, GO:0003674, GO:0022804
GO:0002238 [BP]response to molecule of fungal originprobableGO:0009607, GO:0009620, GO:0050896, GO:0008150, GO:0042221, GO:0051707, GO:0010033, GO:0051704
GO:0015226 [MF]carnitine transmembrane transporter activityprobableGO:0022891, GO:0003674, GO:0022892, GO:0015651, GO:0008028, GO:0005215, GO:0008509, GO:0008324, GO:0022857, GO:0015075, GO:0008514, GO:1901618, GO:0015101, GO:0015199, GO:0005342, GO:0015171, GO:0046943
GO:0070715 [BP]sodium-dependent organic cation transportprobableGO:0006812, GO:0006811, GO:0006810, GO:0044765, GO:0015695, GO:0071702, GO:0008150, GO:0051234, GO:0051179, GO:0044699
GO:0015347 [MF]sodium-independent organic anion transmembrane transporter activityprobableGO:0022891, GO:0022892, GO:0015291, GO:0008514, GO:0005215, GO:0008509, GO:0015075, GO:0022857, GO:0003674, GO:0022804
GO:0031231 [CC]intrinsic to peroxisomal membraneprobableGO:0042579, GO:0043229, GO:0031300, GO:0043227, GO:0043226, GO:0031224, GO:0005737, GO:0044446, GO:0005778, GO:0031090, GO:0016020, GO:0005777, GO:0044439, GO:0044438, GO:0031903, GO:0043231, GO:0044464, GO:0005623, GO:0005622, GO:0005575, GO:0044444, GO:0044424, GO:0044425, GO:0044422
GO:0010248 [BP]establishment or maintenance of transmembrane electrochemical gradientprobableGO:0009987, GO:0006811, GO:0006810, GO:0051179, GO:0034220, GO:0044765, GO:0044763, GO:0008150, GO:0051234, GO:0055085, GO:0044699
GO:0005329 [MF]dopamine transmembrane transporter activityprobableGO:0022891, GO:0022892, GO:0008504, GO:0005215, GO:0008324, GO:0022857, GO:0015075, GO:1901618, GO:0003674, GO:0022804
GO:0048241 [BP]epinephrine transportprobableGO:0065008, GO:0015844, GO:0071702, GO:0051234, GO:0015850, GO:0006810, GO:0051937, GO:0071705, GO:0044765, GO:0008150, GO:0009914, GO:0065007, GO:0010817, GO:0051179, GO:0044699
GO:0046903 [BP]secretionprobableGO:0006810, GO:0044765, GO:0008150, GO:0051234, GO:0051179, GO:0044699
GO:0051608 [BP]histamine transportprobableGO:0015893, GO:0050896, GO:0045117, GO:0006812, GO:0006811, GO:0006810, GO:0042493, GO:0071705, GO:0044765, GO:0008150, GO:0071702, GO:0042221, GO:0051234, GO:0051179, GO:0044699
GO:0005739 [CC]mitochondrionprobableGO:0005737, GO:0043231, GO:0044464, GO:0043229, GO:0005623, GO:0005622, GO:0005575, GO:0044444, GO:0044424, GO:0043227, GO:0043226
GO:0009437 [BP]carnitine metabolic processprobableGO:0044710, GO:0006082, GO:0006577, GO:0009987, GO:0019752, GO:0032787, GO:0071704, GO:0034641, GO:0006807, GO:0008150, GO:0044237, GO:0008152, GO:0043436, GO:0044281, GO:1901615
GO:0006855 [BP]drug transmembrane transportprobableGO:0015893, GO:0009987, GO:0050896, GO:0006810, GO:0042493, GO:0051179, GO:0008150, GO:0044765, GO:0044763, GO:0042221, GO:0051234, GO:0055085, GO:0044699
GO:0015879 [BP]carnitine transportprobableGO:0015718, GO:0015850, GO:0006812, GO:0006811, GO:0006810, GO:0015711, GO:0051179, GO:0071705, GO:0044765, GO:0015849, GO:0008150, GO:0015697, GO:0071702, GO:0015838, GO:0051234, GO:0006820, GO:0044699, GO:0046942
GO:0015874 [BP]norepinephrine transportprobableGO:0015844, GO:0015850, GO:0006810, GO:0051937, GO:0071705, GO:0044765, GO:0008150, GO:0071702, GO:0051234, GO:0051179, GO:0044699
GO:0015871 [BP]choline transportprobableGO:0015850, GO:0006812, GO:0006811, GO:0006810, GO:0071705, GO:0044765, GO:0008150, GO:0071702, GO:0051234, GO:0051179, GO:0044699
GO:0015872 [BP]dopamine transportprobableGO:0015844, GO:0015850, GO:0006812, GO:0006811, GO:0006810, GO:0051937, GO:0071705, GO:0044765, GO:0008150, GO:0071702, GO:0051234, GO:0051179, GO:0044699
GO:0005496 [MF]steroid bindingprobableGO:0097159, GO:0003674, GO:0008289, GO:0005488
GO:0030165 [MF]PDZ domain bindingprobableGO:0003674, GO:0019904, GO:0005515, GO:0005488
GO:0005333 [MF]norepinephrine transmembrane transporter activityprobableGO:0022891, GO:0022892, GO:0008504, GO:0005215, GO:0022857, GO:1901618, GO:0003674, GO:0022804
GO:0030307 [BP]positive regulation of cell growthprobableGO:0045927, GO:0040008, GO:0051128, GO:0001558, GO:0065007, GO:0048518, GO:0008150, GO:0050794, GO:0050789, GO:0048522
GO:0005901 [CC]caveolaprobableGO:0045121, GO:0016020, GO:0044464, GO:0005623, GO:0005575, GO:0071944, GO:0005886, GO:0044425, GO:0044459
GO:0005277 [MF]acetylcholine transmembrane transporter activityprobableGO:0022891, GO:0022892, GO:0005215, GO:0005326, GO:0008324, GO:0015075, GO:0022857, GO:0003674, GO:1901375
GO:0015220 [MF]choline transmembrane transporter activityprobableGO:0022891, GO:0022892, GO:0005215, GO:0008324, GO:0022857, GO:0015075, GO:1901618, GO:0003674, GO:0015665
GO:0007390 [BP]germ-band shorteningprobableGO:0048598, GO:0032502, GO:0001700, GO:0032501, GO:0044707, GO:0048856, GO:0044767, GO:0009790, GO:0009792, GO:0008150, GO:0009653, GO:0007275, GO:0044699
GO:0015742 [BP]alpha-ketoglutarate transportprobableGO:0015849, GO:0006811, GO:0006810, GO:0015711, GO:0044765, GO:0006820, GO:0006835, GO:0071702, GO:0008150, GO:0051234, GO:0051179, GO:0044699, GO:0046942

Prediction of Enzyme Commission Number ?

No EC number assigned to the protein, probably not an enzyme!

Spatial Structural Prediction

Structural Models Based on Templates

Template: 4GC0, chain A
Confidence level:very confident
Coverage over the Query: 153-542
View the alignment between query and template
View the model in PyMOL